Pharma News & Analysis

Tuesday, November 9, 2010

More journals

Three more journals which publish negative results:
http://www.jnrbm.com/
http://www.jnr-eeb.org/index.php/jnr
http://www.arjournals.com/ojs/?journal=Biol&page=about&op=editorialPolicies#focusAndScope
at 7:35:00 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Newer Post Older Post Home

Subscribe To

Posts
Atom
Posts
Comments
Atom
Comments

Popular Posts

  • Funny Clinical Research Cartoons
  • MenAfriVac, meningitis vaccine administered to 100 millionth person
  • Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
  • Access to Medicine Index 2012
  • Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
  • Colleges offering Pharm.D in Andhra Pradesh
  • FDA agrees to review Merck's Suvorexant for sleeplessness
  • New drug approved by US FDA for the treatment of COPD
  • Computer Exercises May Offer New Hope for Alzheimer's Patients
  • Merck Opens New Manufacturing Facility in Hangzhou, China

Blog Archive

  • ►  2024 (1)
    • ►  March (1)
  • ►  2023 (16)
    • ►  November (2)
    • ►  October (7)
    • ►  May (7)
  • ►  2022 (13)
    • ►  September (8)
    • ►  July (3)
    • ►  June (1)
    • ►  April (1)
  • ►  2021 (24)
    • ►  November (13)
    • ►  October (8)
    • ►  September (3)
  • ►  2015 (1)
    • ►  April (1)
  • ►  2014 (4)
    • ►  January (4)
  • ►  2013 (44)
    • ►  December (20)
    • ►  November (10)
    • ►  October (2)
    • ►  September (1)
    • ►  May (3)
    • ►  April (8)
  • ►  2012 (343)
    • ►  December (2)
    • ►  November (5)
    • ►  September (112)
    • ►  August (197)
    • ►  July (5)
    • ►  April (4)
    • ►  March (10)
    • ►  February (3)
    • ►  January (5)
  • ►  2011 (121)
    • ►  December (19)
    • ►  October (9)
    • ►  September (11)
    • ►  August (30)
    • ►  June (9)
    • ►  May (8)
    • ►  April (14)
    • ►  March (11)
    • ►  February (6)
    • ►  January (4)
  • ▼  2010 (105)
    • ►  December (31)
    • ▼  November (10)
      • International Conference on Clinical Trials
      • M.Pharm at BITS Pilani
      • More journals
      • Journal that publishes NEGATIVE RESULTS
      • Suspension of licence to Manufacture/Sale/Distribu...
      • GUIDANCE ON CLINICAL TRIAL INSPECTION
      • Drugs and Cosmetics (Amendment) Act 2008
      • Good Distribution Practices(GDP).
      • Short term courses at NIPER
      • Private partners for NIPERs
    • ►  August (1)
    • ►  June (7)
    • ►  April (9)
    • ►  March (4)
    • ►  February (24)
    • ►  January (19)
  • ►  2009 (222)
    • ►  December (23)
    • ►  November (6)
    • ►  October (9)
    • ►  September (16)
    • ►  August (62)
    • ►  July (32)
    • ►  June (31)
    • ►  May (17)
    • ►  March (15)
    • ►  February (11)
  • ►  2008 (29)
    • ►  December (4)
    • ►  September (1)
    • ►  July (2)
    • ►  June (6)
    • ►  May (1)
    • ►  April (5)
    • ►  March (7)
    • ►  January (3)
  • ►  2007 (3)
    • ►  December (2)
    • ►  October (1)

Topics

pharma (171) regulation (82) drugs (81) Regulatory (63) News (57) Education (55) clinical (51) clinical research (49) FDA (45) clinical trials (40) conference (29) swine flu (28) DCGI (27) Approval (25) India (25) workshop (25) markets (23) admission (19) colleges (19) company news (19) patent (19) seminar (19) job (18) research (18) vacancy (15) courses (14) IPR (11) pharm.d (11) pharmacy (11) New drugs (10) vaccines (10) IPC (9) M.Pharm (9) statistics (9) training (9) CRO (8) WHO (8) cancer (8) diseases (8) government (8) Pharmacopoeia (7) oncology (7) Awards (6) NIPER (6) Pfizer (6) expo (6) healthcare (6) people (6) sales (6) BMS (5) FDC (5) GSK (5) Industry (5) NPPA (5) PCI (5) diabetes (5) exports (5) guidance (5) spurious drugs (5) DTAB (4) DoP (4) ban (4) biotech (4) career (4) certification (4) diagnostics (4) journals (4) pharmacovigilance (4) teaching (4) CDSCO (3) Devices (3) FICCI (3) GATE (3) ICMR (3) IDMA (3) Malaria (3) Novartis (3) Roche (3) articles (3) banned drugs (3) blog (3) generics (3) interview (3) job cuts (3) law (3) market research (3) policy (3) recruitment (3) technology (3) virtual clinical trials (3) AICTE (2) AIDS (2) AIIMS (2) AstraZeneca (2) Ayush (2) BCG (2) Biocon (2) CDA (2) China (2) DLBCL (2) Deal (2) Discovery (2) EMEA (2) Europe (2) GMP (2) HIV (2) Hospital (2) IMS (2) IND (2) IPA (2) Maharastra (2) Manufacturing (2) Merck (2) Ranbaxy (2) SRF (2) Sanofi (2) Strategy (2) Weight loss (2) abstacts (2) adverticle (2) biosimilars (2) chikungunya (2) counselling (2) fraud (2) funny (2) machinery (2) manipal (2) marketing (2) meeting (2) merger (2) pharmacology (2) pricing (2) project (2) side effects (2) tamilnadu (2) testing (2) treatment (2) videos (2) ACTE (1) AIPS (1) ASBMR (1) Access to Medicine (1) Africa (1) Amylin (1) Ardea (1) Arthritis (1) Atropa (1) Awareness (1) BA/BE (1) BITS Pilani (1) British (1) CBER (1) CCMB (1) CCRH (1) CEP (1) CFDA (1) CHMP (1) CII (1) COPD (1) CPHl (1) Chronic Diseases (1) ClinicalTrials.gov (1) Colchicine (1) Crowdsourcing (1) DBT (1) DCA (1) DPCO (1) DPST (1) DST (1) Dapagliflozin (1) Diabetic retinopathy (1) Diptheria (1) Drug discontinuation (1) Drug inspector (1) Elder (1) Electroceuticals (1) Events (1) FDCA (1) FGSCDA (1) FMRAI (1) Febuxostat (1) Formulary (1) GDP (1) GOBIOM (1) GPAT (1) GVK (1) Gene (1) Gout (1) H1N1 (1) HPV (1) Heart failure (1) Hepatitis (1) ICT (1) ILDS (1) IPGA (1) IPSCON (1) IRB (1) ISCR (1) Import (1) Infants (1) Influenza (1) Innocentive (1) Insomnia (1) Internet (1) Investment (1) JOVE (1) JRF (1) JnJ (1) KDPMA (1) Launch (1) Lilly (1) MBA (1) MCI (1) MHRA (1) MedImmune (1) Media (1) Medical (1) Medical Tourism (1) Medicine (1) Medicines (1) Meningitis (1) Monographs (1) Mutation (1) NDA (1) Nanomedicine (1) Neuroscience (1) OAB (1) Obesity (1) Operations (1) Osteoarthritis (1) Ozone Pharma (1) Pharma Industry (1) Pharmexcil (1) Phase IV (1) Pipeline (1) Pneumonia (1) Preclinical (1) QA (1) QIP (1) Reference (1) SMS (1) Smoking (1) Standards (1) Sun Pharma (1) TB (1) TNCDA (1) Takeda (1) Teijin (1) Tetanus (1) Thyroid (1) Tobacco (1) UGC (1) UK (1) URL pharma (1) US (1) Wyeth (1) accredition (1) adverse effects (1) albinism (1) alternative medicine (1) amgen (1) bihar (1) bill (1) biomarker (1) biopharm (1) brain fever (1) budget (1) campaign (1) cisapride (1) contest (1) counterfeit (1) court (1) cpcsea (1) cytrx (1) degree (1) delhi (1) depression (1) device (1) diet (1) draft (1) drugs control (1) economy (1) ethics (1) exam (1) faculty (1) grants (1) hyderabad (1) info (1) informed consent (1) innovation (1) inspection (1) international (1) jobs (1) karnataka (1) kerala (1) lab (1) lesinurad (1) loans (1) misconduct (1) new year (1) nimesulide (1) novo nordisk (1) nuts (1) orchid (1) osteoporosis (1) overpricing (1) parliament (1) peanuts (1) pharmacogenomics (1) phase I (1) pictures (1) pollution (1) product safety (1) profit (1) rajasthan (1) recognition (1) report (1) resistance (1) reward (1) salary (1) scholarships (1) serum institute (1) sibutramine (1) skin cancer (1) soft tissue sarcoma (1) sri lanka (1) stiefel (1) stockists (1) support (1) survey (1) symposia (1) tanzania (1) thanks (1) transplantation (1) updates (1) virus (1) what to name it (1) youtube (1)
Copyright© 2016, Pharma News & Analysis. Powered by Blogger.